SCHEMBL9708991

SCHEMBL9708991

O=c1c2ccccc2[nH]c2cc(F)ccc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.80
ALDH1A1 P00352 3/20 0.80
KDM4E B2RXH2 2/20 0.80
GLA P06280 2/20 0.80
HTT P42858 2/20 0.80
LMNA P02545 3/20 0.67
HPGD P15428 3/20 0.67
ATM Q13315 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
CCNE2 O96020 1/20 0.59
CDK4 P11802 1/20 0.59
CCND1 P24385 1/20 0.59
CCNE1 P24864 1/20 0.59
CDK2 P24941 1/20 0.59
CAMK2B Q13554 1/20 0.59
CAMK2G Q13555 1/20 0.59
CAMK2D Q13557 1/20 0.59
CAMK2A Q9UQM7 1/20 0.59
MEN1 O00255 2/20 0.54
POLB P06746 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14598932 0.89 GAA (0.93) GAAALDH1A1KDM4EGLAHTT
SCHEMBL276017 0.89 ALDH1A1 (0.65) GAAALDH1A1KDM4EGLAHTT
SCHEMBL5444428 0.89 ALDH1A1 (1.00) GAAALDH1A1KDM4EGLAHTT
SCHEMBL6756610 0.88 AHR (0.64) GAAALDH1A1KDM4EGLAHTT
SCHEMBL29562978 0.88 AHR (0.64) GAAALDH1A1KDM4EGLAHTT
SCHEMBL870205 0.86 KDM4E (0.65) GAAALDH1A1KDM4EGLAHTT
SCHEMBL92077 0.82 GAA (0.82) GAAALDH1A1KDM4EGLAHTT
SCHEMBL13412901 0.82 GAA (0.82) GAAALDH1A1KDM4EGLAHTT
SCHEMBL22367061 0.82 GAA (0.82) GAAALDH1A1KDM4EGLAHTT
SCHEMBL29349876 0.82 GAA (0.82) GAAALDH1A1KDM4EGLAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3535243-B1 SUBSTITUTED 9H-XANTHEN-9-ONE, 9H-THIOXANTHEN-9-ONE AND ACRIDIN-9(10H)-ONE DERIVATIVES AND RELATED COMPOUNDS CSF-1R INHIBITORS FOR THE TREATMENT OF CANCER AUCKLAND UNISERVICES LTD (NZ) 2021-12-15 EP disclosed
US-11028064-B2 Tricyclic heterocyclic derivatives and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2021-06-08 US disclosed
US-20190276423-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2019-09-12 US disclosed
US-9960366-B2 Organic light emitting element CANON KABUSHIKI KAISHA (JP) 2018-05-01 US disclosed
US-20160211467-A1 ORGANIC LIGHT EMITTING ELEMENT CANON KABUSHIKI KAISHA (JP) 2016-07-21 US disclosed
EP-0471516-A1 Tricyclic heterocyclic derivatives IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-02-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11028064-B2 Tricyclic heterocyclic derivatives and uses thereof CSF3R, CSF1R, FLT3 GAA 1415/4885ALDH1A1 2524/4885KDM4E 2855/4885
US-20190276423-A1 TRICYCLIC HETEROCYCLIC DERIVATIVES AND USES THEREOF CSF3R, CSF1R, FLT3 GAA 1415/4885ALDH1A1 2524/4885KDM4E 2855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.